Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 4
2007 1
2009 3
2010 5
2011 4
2012 4
2013 10
2014 12
2015 21
2016 17
2017 10
2018 7
2019 8
2020 11
2021 7
2022 4
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Xu-Monette ZY, Li Y, Snyder T, Yu T, Lu T, Tzankov A, Visco C, Bhagat G, Qian W, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Wang Y, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Fan X, van Krieken JH, Piris MA, Winter JN, Au Q, Kirsch I, Zhang M, Shaughnessy J, Xu B, Young KH. Xu-Monette ZY, et al. Among authors: dybkaer k. Clin Cancer Res. 2023 Dec 1;29(23):4808-4821. doi: 10.1158/1078-0432.CCR-23-1554. Clin Cancer Res. 2023. PMID: 37728879
Predictive biomarkers in radioresistant rectal cancer: A systematic review.
Slipsager A, Henrichsen SN, Falkmer UG, Dybkær K, Belting M, Poulsen LØ. Slipsager A, et al. Among authors: dybkaer k. Crit Rev Oncol Hematol. 2023 Jun;186:103991. doi: 10.1016/j.critrevonc.2023.103991. Epub 2023 Apr 13. Crit Rev Oncol Hematol. 2023. PMID: 37059272 Free article. Review.
Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital.
Ladekarl M, Nøhr AK, Sønderkær M, Dahl SC, Sunde L, Vestereghem C, Mapendano CK, Haslund CA, Pagh A, Carus A, Lörincz T, Nowicka-Matus K, Poulsen LØ, Laursen RJ, Dybkær K, Poulsen BK, Frøkjær JB, Brügmann AH, Ernst A, Wanders A, Bøgsted M, Pedersen IS. Ladekarl M, et al. Among authors: dybkaer k. Acta Oncol. 2023 Mar;62(3):261-271. doi: 10.1080/0284186X.2023.2185542. Epub 2023 Mar 11. Acta Oncol. 2023. PMID: 36905645
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential.
Li Y, Xu-Monette ZY, Abramson J, Sohani AR, Bhagat G, Tzankov A, Visco C, Zhang S, Dybkaer K, Pan Z, Xu M, Tam W, Zu Y, Hsi ED, Hagemeister FB, Go H, van Krieken JH, Winter JN, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Wang Y, Zhang M, Young KH. Li Y, et al. Among authors: dybkaer k. Blood Adv. 2023 Apr 11;7(7):1308-1311. doi: 10.1182/bloodadvances.2022008550. Blood Adv. 2023. PMID: 36399513 Free PMC article. No abstract available.
Hsp90 inhibition sensitizes DLBCL cells to cisplatin.
Schmidt L, Issa II, Haraldsdóttir H, Hald JL, Schmitz A, Due H, Dybkær K. Schmidt L, et al. Among authors: dybkaer k. Cancer Chemother Pharmacol. 2022 Apr;89(4):431-440. doi: 10.1007/s00280-022-04407-5. Epub 2022 Feb 21. Cancer Chemother Pharmacol. 2022. PMID: 35190872 Free PMC article.
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N, Sonneveld P, Dybkær K. Schmitz A, et al. Among authors: dybkaer k. BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1. BMC Cancer. 2022. PMID: 35123422 Free PMC article.
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.
Albitar M, Zhang H, Goy A, Xu-Monette ZY, Bhagat G, Visco C, Tzankov A, Fang X, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Young KH. Albitar M, et al. Among authors: dybkaer k. Blood Cancer J. 2022 Feb 1;12(2):25. doi: 10.1038/s41408-022-00617-5. Blood Cancer J. 2022. PMID: 35105854 Free PMC article.
127 results